Evidence map›Paper›PMID 30054715›Full record

ReviewHerz2020

[Antagonistic function of the heart muscle : Part II: Clinical implications].

P P Lunkenheimer, P Niederer, J M Lunkenheimer, K Redmann, M Smerup, B Schmitt, W Saggau, R J V Batista

Abstract readReview
PubMed Publisher
In one paragraph

Review in Herz, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 86% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 7 institutions in 3 countries.

P P LunkenheimerExperimentelle Thorax‑, Herz- und Gefäßchirurgie, Universitätskliniken Münster, Münster, Deutschland. P.P.Lunkenheimer@web.de.ORCID http://orcid.org/0000-0002-3881-622X
P NiedererInstitute of Biomedical Engineering, ETH and University Zürich, Zürich, Schweiz.
J M LunkenheimerKrankenhaus der Augustinerinnen/Severinsklösterchen, Jakobstr. 27-31, Köln, Deutschland.
K RedmannUniversitätskliniken, Münster, Deutschland.
M SmerupThoraxkirurgisk Klinik, University Hospital, Kopenhagen, Dänemark.
B SchmittAbteilung für angeborene Herzfehler, Deutsches Herzzentrum, Berlin, Deutschland.
W SaggauKlinik für Herzchirurgie, Klinikum Ludwigshafen, Ludwigshafen, Deutschland.
R J V Batista, Rua Carlos Rasera 8, Vista Alegre, Curitiba PR, Brasilien.
Deutsches Herzzentrum der Charité · DEFundação Carlos Chagas · BRInstitute for Biomedical Engineering · CHKlinikum Ludwigshafen · DEKlinik und Poliklinik für Psychosomatik und Psychotherapie · DEKrankenhaus der Augustinerinnen · DEUniversity of Münster · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the hypertrophic heart the myostructural afterload in the form of endoepicardial networks is predominant, which enhances myocardial hypertrophy. The intrinsic antagonism is derailed. Likewise, the connective tissue scaffold, i.e. the stromatogenic afterload, is enriched in the response to the derailment of antagonism in a hypertrophic heart up to regional captivation of the heart musculature. Due to the selective susceptibility of the auxotonic, contracting oblique transmural myocardial network for low dose negative inotropic medication, this promises to attenuate progress in myocardial hypertrophy. Volume reduction surgery is most effective in reducing wall stress as long as the myocardium is not critically fettered by fibrosis. The use of external mechanical circulatory support is then effective if the heart is supported in its resting mode, which means around a middle width and at minimal amplitude of motion. The takotsubo cardiomyopathy might possibly reflect an isolated, extreme stimulation of the intrinsic antagonism as a response to hormonally induced sensitization of the myocardium to catecholamine. A particular significant conclusion with respect to the diseased heart is that clinical diagnostics need new impulses with a focus on the analysis of local motion patterns and on myocardial stiffness reflecting disease-dependent antagonistic intensity. This would become a relevant diagnostic marker if corresponding (noninvasive) measurement techniques would become available.

Indexed as

Cardiomyopathy, HypertrophicHeartMyocardiumTakotsubo CardiomyopathyCardiomegalyFibrosisHumansCirculatory supportDerailed antagonismMyocardial hypertrophyTakotsubo cardiomyopathyVolume reduction surgery

Identifiers

PMID30054715
OpenAlexW2883987756

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.